*March 2022*
Jill Feldman, EGFR Resisters co-founder, participated in one of the FDA’s Conversations on Cancer public panel discussions, “More Isn’t Always Better- Understanding Cancer Treatment Tolerability.” Watch video here.
*March 2022*
Jill Feldman, EGFR Resisters co-founder, participated in one of the FDA’s Conversations on Cancer public panel discussions, “More Isn’t Always Better- Understanding Cancer Treatment Tolerability.” Watch video here.





The EGFR Resisters is a global community of patients and caregivers impacted by EGFR-positive lung cancer. We’re here to share knowledge, offer support and collaborate to drive progress in research and care. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.
